AusFoodtech welcomes first National Food Plan
28 May, 2013AusFoodtech has welcomed the release of Australia’s first National Food Plan - a road map for Australia’s food businesses and consumers.
12 months on: REVA presents stent trial follow-up results
27 May, 2013 by Dylan Bushell-EmblingTwelve-month, follow-up data from the first eight patients enrolled in a trial of REVA Medical’s (ASX:RVA) bioresorbable coronary stent supports the safety of the product.
BioDiem secures Japanese patent for BDM-I
24 May, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has picked up a Japanese patent covering antimicrobial BDM-I as a treatment for malaria and trichomoniasis.
IDT Australia announces board shake-up
24 May, 2013 by Dylan Bushell-EmblingCMO IDT Australia (ASX:IDT) has announced the pending replacement of two current board members.
Griffith Hack attracts top patent attorney
23 May, 2013IP firm Griffith Hack has welcomed the arrival of Dr Tony Davis as a Senior Associate to its growing Life Sciences and Chemical practice.
AusBiotech opposes changes to export grants scheme
23 May, 2013AusBiotech has joined several industry groups to express concern over the Export Market Development Grants (EMDG) Amendment Bill.
Local CROs team up for international trials
22 May, 2013 by Dylan Bushell-EmblingDatapharm is on the expansion path for Dai-Sys, its initiative aimed at bringing together a global network of local small to mid-size CROs for international clinical trial support services.
Alchemia teams with Merck Serono for cancer trial
22 May, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has announced a collaborative trial of HA-Irinotecan with Merck Serono’s Erbitux and blamed seasonal factors for falling quarterly fondaparinux sales.
Industry Innovation Precincts applications open
21 May, 2013As part of the federal government’s Innovation and Industry Policy ‘A Plan for Australian Jobs’, released in February, applications have opened for up to eight Industry Innovation Precincts.
Agreement signed between Garvan, Cancer Therapeutics CRC and SYNkinase
20 May, 2013The development of a new research tool for proteomics and chemical biology is set to move forward.
New spin-out company to develop nanoparticle drugs
16 May, 2013A new spin-out company has been set up by the University of Western Australia to commercialise nanoparticle drugs for biomedical applications.
Revised code to benefit ASX-listed life science companies
16 May, 2013The Minister for Technology, the Hon Gordon Rich-Phillips, yesterday joined forces with the Australian Securities Exchange (ASX) and Australia’s biotechnology industry association, AusBiotech, to launch a revised edition of the industry code of best practice that will support capital formation by ASX-listed life science companies.
REVA appoints new managing director
15 May, 2013 by Dylan Bushell-EmblingMichel Vanbrabant will joint REVA Medical (ASX:RVA) as managing director to help the company prepare its EU market strategy for bioresorbable coronary scaffold ReZolve2.
pSivida posts $2.8m loss for Q3
15 May, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) says its net loss grew slightly in Q3, as it awaits revenue and royalty payments from partner Alimera for the Iluvien insert.
Phosphagenics and US agency target cow infection
15 May, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) and a US Department of Agriculture research agency will jointly formulate and test products aimed at fighting the bacterial infection mastitis in dairy cows.
